1.广州市妇女儿童医疗中心妇产科,广东 广州 510120
2.中山大学肿瘤防治中心分子诊断科,广东 广州 510060
3.南方医科大学附属中山博爱医院检验科,广东 中山 528400
蔡春芳,副主任医师,研究方向:妇产科学,E-mail:938767505@qq.com
纸质出版日期:2022-05-20,
收稿日期:2022-01-21,
扫 描 看 全 文
蔡春芳,古家美,官燕飞.外周血循环细胞和三种肿瘤标志物检测对Ⅰ期子宫内膜癌的诊断价值[J].中山大学学报(医学科学版),2022,43(03):471-479.
CAI Chun-fang,GU Jia-mei,GUAN Yan-fei.Diagnostic Value of Peripheral Blood Circulating Tumor Cells and Three Tumor Markers in Stage I Endometrial Carcinoma[J].Journal of Sun Yat-sen University(Medical Sciences),2022,43(03):471-479.
蔡春芳,古家美,官燕飞.外周血循环细胞和三种肿瘤标志物检测对Ⅰ期子宫内膜癌的诊断价值[J].中山大学学报(医学科学版),2022,43(03):471-479. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2022.0315.
CAI Chun-fang,GU Jia-mei,GUAN Yan-fei.Diagnostic Value of Peripheral Blood Circulating Tumor Cells and Three Tumor Markers in Stage I Endometrial Carcinoma[J].Journal of Sun Yat-sen University(Medical Sciences),2022,43(03):471-479. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2022.0315.
目的
2
探讨外周血循环肿瘤细胞(CTC)和三种肿瘤标志物检测对Ⅰ期子宫内膜癌(EC)的诊断价值,为寻找一种无创的早期EC诊断方法提供科学依据。
方法
2
选取2016年5月至2021年11月期间,335例健康女性体检者(对照组)、291例子宫内膜良性病变患者(良性病变组)、268例Ⅰ期EC患者(EC组)为研究对象,抽取体检者,患者的术前静脉血液标本3.2 mL,采用免疫荧光杂交和染色技术测定CTC水平,乳胶增强免疫比浊法测定SAA水平,电化学发光法测定HE4、CA125水平,观察3组研究对象的CTC、SAA、HE4、CA125阳性率及水平差异,比较CTC、SAA、HE4、CA125、(SAA+HE4+CA125)、(CTC+SAA+HE4+CA125)检测对Ⅰ期EC诊断的灵敏度、特异度、符合率、阳性预测值、阴性预测值、约登指数和受试者工作特征(ROC)曲线面积(AUC)的差异。
结果
2
①CTC、SAA、HE4、CA125、(SAA+ HE4+CA125)、(CTC+ SAA+ HE4+CA125)检测在EC组的阳性率均高于对照组和良性病变组,差异均具有统计学意义(
P
<
0.01)。在良性病变组中,(CTC+HE4+SAA+CA125)检测的阳性率高于其他检测指标,与HE4、CTC检测比较,差异具有统计学意义(
χ
2
=8.58,
P
=0.003;
χ
2
=33.26,
P
<
0.001)。在EC组中,(CTC+ HE4+SAA+CA125)检测的阳性率高于其他检测指标,与CTC、SAA、HE4、CA125、(SAA+HE4+CA125)检测比较,差异具有统计学意义(
P
<
0.001)。②EC组的CTC、SAA、HE4、CA125表达水平最高,与对照组、良性病变组比较,差异具有统计学意义(
P
<
0.001)。③(CTC+SAA+HE4+CA125)检测诊断Ⅰ期EC的灵敏度和符合率度最高,阴性预测值和约登指数最大。④CTC、SAA、HE4、CA125、(SAA+HE4+CA125)、(CTC+SAA+HE4+CA125)检测的AUC分别为0.86、0.81、0.75、0.78、0.82、0.95。
结论
2
(CTC+SAA+HE4+CA125)检测对诊断Ⅰ期EC具有较高的灵敏度、符合率、阴性预测值、约登指数,较大的AUC,是一种诊断早期EC的较佳组合模式。
Objective
2
To investigate the diagnostic value of peripheral blood circulating tumor cells (CTC)and three tumor markers in stage I endometrial carcinoma (EC), so as to provide a scientific basis for finding a noninvasive early diagnosis method of EC.
Methods
2
From May 2016 to November 2021, 335 healthy female physical examinees (control group), 291 patients with benign endometrial lesions (benign lesion group) and 268 patients with stage I EC (EC group) were selected as the research subjects. Samples of 3.2 mL cephalic vein blood were taken from the three groups of subjects composed of the physical examinees and patients before operation. The CTC level was measured by immunofluorescence hybridization and staining. The levels of SAA were measured by latex enhanced immunoturbidimetry, and HE4 and CA125 were measured by electrochemiluminescence. The positive rates and level differences of CTC, SAA, HE4 and CA125 in the three groups were observed. The sensitivity, specificity, coincidence rate, positive predictive value, negative predictive value of CTC, SAA, HE4, CA125, (SAA+HE4+CA125), (CTC+SAA+HE4+CA125) in the diagnosis of stage I EC were compared Difference between yoden index and receiver operating characteristic (ROC) curve area (AUC).
Results
2
①The positive rates of CTC, SAA, HE4, CA125, (SAA+HE4+CA125), (CTC+SAA+HE4+CA125) in EC group were higher than those in control group and benign lesion group (
P
<
0.01). In the benign lesion group, the positive rate of (CTC+HE4+SAA+CA125) was higher than that of other detection indexes. Compared with HE4 and CTC, the difference was statistically significant(
χ
2
=8.58,
P
=0.003;
χ
2
=33.26,
P
<
0.001). In EC group, the positive rate of (CTC+HE4+SAA+CA125) was higher than that of other detection indexes. Compared with CTC, SAA, HE4, CA125, (SAA+HE4+CA125), the difference was statistically significant (
P
<
0.001). ②The expression levels of CTC, SAA, HE4 and CA125 in EC group were the highest, which was statistically significant compared with the control group and benign lesion group (
P
<
0.001). ③(CTC+SAA+HE4+CA125) had the highest sensitivity and coincidence rate, negative predictive value and Jordan index. ④The AUC detected by CTC, SAA, HE4, CA125, (SAA+HE4+CA125), (CTC+SAA+HE4+CA125) were 0.86, 0.81, 0.75, 0.78, 0.82 and 0.95, respectively.
Conclusions
2
(CTC+SAA+HE4+CA125) detection has high sensitivity, coincidence rate, negative predictive value, Jordan index and large AUC for the diagnosis of stage I EC. It is a better combination model for the diagnosis of early EC.
循环肿瘤细胞血清淀粉样蛋白A人附睾蛋白4糖类抗原125子宫内膜癌
circulating tumor cellserum amyloid Ahuman epididymal protein 4carbohydrate antigen 125endometrial carcinoma
Huvila J, Pors J, Thompson EF, et al. Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis[J]. J Pathol, 2021, 253(4):355-365.
谢玲玲,林荣春,林仲秋. 《2021 NCCN子宫肿瘤临床实践指南(1版)》解读[J].中国实用妇科与产科杂志, 2021, 37(1):75-81.
Xie LL, Lin RC, Lin ZQ. Interpretation of 《2021 NCCN clinical practice guide for uterine tumors (1st Edition)》[J]. Chin J of Prac Gynecol Obstet, 2021, 37(1):75-81.
Espiau Romera A, Cuesta Guardiola T, Benito Vielba M, et al. HE4 tumor marker as a predictive factor for lymphatic metastasis in endometrial cancer[J]. Int J Gynaecol Obstet, 2020, 149(3):265-268.
Cymbaluk-Płoska A, Gargulińska P, Bulsa M, et al. Can the determination of HE4 and CA125 markers affect the treatment of patients with endometrial cancer?[J]. Diagnostics (Basel), 2021, 11(4):626.
梁馨元,谭碧波,梁丁丁,等. 循环肿瘤细胞在妇科恶性肿瘤诊断,治疗指导,预后判断中的应用进展[J].山东医药,2020,60(36):84-87.
Liang XY, Tan BB, Liang DD, et al. Application progress of circulating tumor cells in diagnosis, treatment guidance and prognosis of gynecological malignant tumors[J]. Shandong Med, 2020, 60(36):84-87.
陈志强,米贤军,陈昂,等. 外周血循环肿瘤细胞检测在筛查卵巢上皮性癌中的应用[J].中山大学学报(医学版), 2018,39(6):891-896.
Chen ZQ, Mi XJ, Chen A, et al. Preliminary study of peripheral blood circulating tumor cell detection in screening of ovarian epithelial cancer[J]. J Sun Yat-Sen Univ (Medical Sciences), 2018, 39(6):891-896.
官燕飞,陈志强,袁春雷,等. 基于外周血循环肿瘤细胞和ROMA指数联合检测在早期卵巢上皮性癌诊断中的初步评价[J]. 南京医科大学学报(自然科学版), 2020,40(4):570-574.
Guan YF, Chen ZQ, Yuan CL, et al. Preliminary evaluation of combined detection of peripheral blood circulating tumor cells and ROMA index in the diagnosis of early ovarian epithelial carcinoma[J]. J Nanjing Med Univ (Natural Sciences), 2020, 40(4):570-574.
官燕飞,陈志强,袁春雷,等. 外周血循环肿瘤细胞、糖类抗原153、糖类抗原125、癌胚抗原检测对105例乳腺导管原位癌或伴微小浸润癌的诊断价值[J].山东大学学报(医学版),2020,58(2):72-78.
Guan YF, Chen ZQ, Yuan CL, et al. Detection of tumor cells, carbohydrate antigen 153, carbohydrate antigen 125 and carcinoembryonic antigen in peripheral blood circulation in 105 cases of ductal carcinoma in situ or with minimal invasive carcinoma[J]. J Shandong Univ (Health Sciences), 2020, 58(2):72-78.
卢珊珊,沈丹华. 第5版WHO女性生殖器官肿瘤分类的更新及解读[J].中华妇产科杂志,2021,56(8):588-592.
Lu SS, Shen DH. Update and interpretation of WHO classification of female genital tumors (5th Edition) [J]. Chin J Obstet Gynecol, 2021, 56(8):588-592.
王建东,孔为民,姜昊. 国际妇产科联盟2018年宫颈癌分期及有关问题[J].中华肿瘤杂志,2020,42(2):94-98.
Wang JD, Kong WM, Jiang H. FIGO 2018 staging of cervical cancer and related issues[J]. Chin J Oncol, 2020, 42(2):94-98.
Trojano G, Olivieri C, Tinelli R, et al. Conservative treatment in early stage endometrial cancer: a review[J]. Acta Biomed, 2019,90(4):405-410.
中国抗癌协会妇科肿瘤专业委员会.子宫内膜癌诊断与治疗指南(2021年版) [J].中国癌症杂志,2021,31(6):501-511.
Gynecological Oncology Committee of China Anti-Cancer Association. Guidelines for the diagnosis and treatment of endometrial cancer (2021 Edition)[J]. Chin Oncology, 2021, 31(6):501-511.
Parsons MW, Francis S, Maurer KA, et al. Refusal of radiation results in inferior survival in endometrial cancer[J]. Am J Clin Oncol, 2020, 43(6):399-410.
Yen TT, Wang TL, Fader AN, et al. Molecular classification and emerging targeted therapy in endometrial cancer[J]. Int J Gynecol Pathol, 2020, 39(1):26-35.
李玲霞,李佳,刘淑娟,等. 循环肿瘤细胞检测在子宫内膜癌患者的临床意义[J]. 山西医科大学学报, 2019,50(5):664-667.
Li LX, Li J, Liu SJ, et al. Clinical significance of circulating tumor cells in patients with endometrial carcinoma[J]. J Shanxi Med Univ, 2019, 50(5):664-667.
黄珊瑜,李小毛,叶辉霞,等. 循环肿瘤细胞与子宫内膜癌临床病理特征关系分析[J].广东医学,2020,41(3):252-256.
Huang SY, Li XM, Ye HX, et al. The correlation between circulating tumor cells and the clinicopathological characteristic of endometrial carcinoma[J]. Guangdong Med J, 2020, 41(3):252-256.
Kiss I, Kolostova K, Pawlak I, et al. Circulating tumor cells in gynaecological malignancies[J]. J Buon, 2020, 25(1):40-50.
Faria SC,Sagebiel T,Patnana M,et al. Tumor markers:myths and facts unfolded[J].Abdom Radiol (NY),2019,44(4):1575-1600.
Castro-Giner F, Aceto N. Tracking cancer progression: from circulating tumor cells to metastasis[J]. Abdom Radiol, 2020, 12(1):31.
黄祥奇,李文娟,梁静,等.循环肿瘤细胞分型与非小细胞肺癌临床病理特征相关性研究[J].新医学,2020,51(12):933-938.
Huang XQ,Li WJ,Liang J,et al. Correlation between types of circulating tumor cells and clinicopathological features of patients with non-small cell lung cancer[J]. J New Med,2020,51(12):933-938.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构